Jonathan Van-Tam on COVID’s Next Phase
Former UK Deputy Chief Medical Officer discusses new protein-based vaccines, declining uptake, and the ongoing risks of COVID-19
-
By
-
James Strachan
-
Julian Upton
-
April 14, 2026
-
Clinical Scorecard: Jonathan Van-Tam on COVID’s Next Phase
At a Glance
| Category | Detail |
|---|
| Condition | COVID-19 |
| Key Mechanisms | Vaccination strategies including mRNA and protein-based vaccines. |
| Target Population | Vulnerable populations and the general public. |
| Care Setting | Public health vaccination programs. |
Key Highlights
- COVID-19 remains a public health concern similar to seasonal flu.
- Nuvaxovid, a protein-based vaccine, is introduced into the UK vaccination program.
- Diverse vaccine technologies are crucial for pandemic preparedness.
- Older populations are at higher risk for severe outcomes from infections.
- Research opportunities arise from using multiple vaccine platforms.
Guideline-Based Recommendations
Diagnosis
- Monitor COVID-19 hospitalizations and deaths.
Management
- Incorporate a variety of vaccine types in public health strategies.
Monitoring & Follow-up
- Track vaccination rates and public health outcomes.
Risks
- Consider the ongoing impact of COVID-19 on vulnerable populations.
Patient & Prescribing Data
Individuals eligible for COVID-19 vaccination, particularly vulnerable groups.
Nuvaxovid provides a non-mRNA option that may address vaccine hesitancy.
Clinical Best Practices
- Ensure rapid access to a range of vaccine technologies.
- Focus on adult vaccination as populations age.
- Explore the potential benefits of alternating vaccine types.
References
